Beit Jala Pharmaceutical Co (XPAE:BJP) EBIT: JOD Mil (TTM As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Beit Jala Pharmaceutical Co EBIT?

Beit Jala Pharmaceutical Co XPAE:BJP EBIT is JOD Mil as of . 20. The stock has 1 warning sign investors should review.

Beit Jala Pharmaceutical Co's earnings before interest and taxes (EBIT) for the six months ended in . 20 was JOD0.00 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EBIT is also linked to Joel Greenblatt's definition of earnings yield.


Beit Jala Pharmaceutical Co  (XPAE:BJP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Beit Jala Pharmaceutical Co's annualized ROC % for the quarter that ended in . 20 is calculated as:

ROC % (Q: . 20 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: . 20 ) + Invested Capital (Q: . 20 ))/ count )
= * ( 1 - % )/( ( + )/ )
=/
= %

where

Note: The Operating Income data used here is one times the annual (. 20) data.

2. Joel Greenblatt's definition of Return on Capital:

Beit Jala Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in . 20 is calculated as:

ROC (Joel Greenblatt) %(Q: . 20 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: . 20  Q: . 20
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=/( ( ( + max(, 0)) + ( + max(, 0)) )/ )
=/( ( + )/ )
=/
= %

where Working Capital is:

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

Working Capital(Q: . 20 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=( + + ) - ( + + )
=

When net working capital is negative, 0 is used.

Note: The EBIT data used here is one times the annual (. 20) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Beit Jala Pharmaceutical Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: . 20 )
=/0.000
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beit Jala Pharmaceutical Co EBIT Related Terms


Beit Jala Pharmaceutical Co EBIT Historical Data

* Premium members only.

The historical data trend for Beit Jala Pharmaceutical Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beit Jala Pharmaceutical Co EBIT Chart

Beit Jala Pharmaceutical Co Annual Data
Trend
EBIT

Beit Jala Pharmaceutical Co Semi-Annual Data
EBIT

XPAE:BJP vs : EBIT Comparison

For the Biotechnology subindustry, Beit Jala Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beit Jala Pharmaceutical Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Beit Jala Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Beit Jala Pharmaceutical Co's EV-to-EBIT falls into.



Beit Jala Pharmaceutical Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in . 20 was JOD Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of JOD Mil mean?
Beit Jala Pharmaceutical Co (XPAE:BJP) has a EBIT of JOD Mil as of . 20. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Beit Jala Pharmaceutical Co.
Is Beit Jala Pharmaceutical Co's EBIT too high?
Beit Jala Pharmaceutical Co's current EBIT is JOD Mil.
How does Beit Jala Pharmaceutical Co's EBIT compare to ?
Beit Jala Pharmaceutical Co's EBIT of JOD Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Beit Jala Pharmaceutical Co. Beit Jala Pharmaceutical Co's current EBIT is JOD Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beit Jala Pharmaceutical Co stock overvalued right now?
Beit Jala Pharmaceutical Co (XPAE:BJP) has a current EBIT of JOD Mil. The current EBIT is JOD Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Beit Jala Pharmaceutical Co (XPAE:BJP), the current EBIT is JOD Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beit Jala Pharmaceutical Co Business Description

Comparable Companies
Address 81, Al-Madares Street, Beit Jala, West Bank, Beit Jala, PSE, 97300
Beit Jala Pharmaceutical Co is a manufacturer of pharmaceutical products. The company's products include tablets, capsules, powders, syrups, solutions, oral drops, creams, gels, lotions, medicated shampoo, suppositories and ointments.